Ticker brief

VRTX VERTEX PHARMACEUTICALS INC

Consumer, Non-cyclical · Biotechnology

last close
$528.04
1 day
+6.0%
14 days
+16.9%
mkt cap
$134.0B
signals 14d
26
authors 14d
20
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-03 · now +0.45 (−1 bearish … +1 bullish)
Who spoke20
authorgradetrader scoresignalsmean sent
@adamfeuersteinA+1.053-0.02
@KunnuInvestsC-0.403+0.58
@ralliesarenaC-1.812+0.05
@afortunetradingC+0.442+0.35
@TheMarket_MonkC-1.531+0.35
@RachelDashCSC-0.271+0.55
@PolarizingLitC+0.261+0.55
@DonDrapperrB+0.401+0.35
@PersimmonTIA-0.321+0.00
@JaguarAnalyticsB+0.011+0.35
@BioStocksC-0.391+0.55
@InvestmentGuru_C+0.031+0.35
@AlertsAndNewsC+1.521+0.50
@EmmanuelInvestC-1.121+0.55
@MartyCharginC-0.721+0.50
@TheProfInvestorC+0.271+0.45
@BiopharmIQB·1+0.50
@TWFeditorC+0.571+0.30
@fj_nextstageC+1.071+0.15
@AsafNaamaniC-2.111+0.45
Recent signals26of 26 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-03@AsafNaamani+0.45Healthcare recap lists breakouts, bases and retests across sector names.
2026-07-02@fj_nextstage+0.15MarketSurge breakout and pivot watch list with IBD exposure reduced.
2026-07-02@KunnuInvests+0.65VRTX breakout confirmed with volume; author says send it higher.
2026-07-02@TWFeditor+0.30Says rotation helps VRTX recover for biotech ETF holders.
2026-07-02@BiopharmIQ+0.50Biotech catalyst roundup cites clinical data, approval, FDA news, and financing.
2026-07-02@TheProfInvestor+0.45Calls for positioning in leading healthcare and banks amid rotation.
2026-07-02@afortunetrading+0.35Cites relative strength and rotation from SMH stocks into software and healthcare.
2026-07-02@adamfeuerstein-0.10Genetix CEO claims leadership in sickle cell gene therapy, with peers mentioned.
2026-07-02@adamfeuerstein-0.25Genetix CEO criticizes Casgevy and Beam effort; author notes no proof.
2026-07-02@MartyChargin+0.50FDA approved expanded CASGEVY use to children ages 2 and older.
2026-07-01@EmmanuelInvest+0.55Vertex received FDA approval expanding CASGEVY to children age 2+ with SCD or TDT.+6.0%
2026-07-01@AlertsAndNews+0.50Vertex announces US FDA approval for expanded CASGEVY use.+6.0%
2026-07-01@InvestmentGuru_+0.35Bullish biotech watchlist and long-term sector rotation thesis.+6.0%
2026-07-01@BioStocks+0.55FDA approves first gene therapy for young children with SCD.+6.0%
2026-06-30@KunnuInvests+0.65Will buy VRTX pullback or breakout — Author says VRTX has bullish HTF setup and will buy pullback or breakout.+6.3%
2026-06-28@JaguarAnalytics+0.35Says large pharma names have all been rocket ships lately.+7.5%
2026-06-28@PersimmonTI+0.00Shares Nature Medicine piece on late-stage and approved kidney disease therapies.+7.5%
2026-06-26@DonDrapperr+0.35Bullish framework for defensive healthcare names during Nasdaq weakness.+7.5%
2026-06-26@afortunetrading+0.35Lists relative-strength names and says IBB/XBI sector looks good.+7.5%
2026-06-25@KunnuInvests+0.45Author is already riding LLY from $907 and likes VRTX and CAH charts.+10.0%
2026-06-25@ralliesarena+0.00Gemini trimmed its Vertex holdings in an AI arena portfolio.+10.0%
2026-06-25@PolarizingLit+0.55Reports gene therapy functionally cures a sickle-cell patient.+10.0%
2026-06-23@RachelDashCS+0.55Lists chart patterns, support/resistance and measured moves for PGR, SPGI, VRTX and SYK.+12.7%
2026-06-22@TheMarket_Monk+0.35Lists stocks with bullish weekly EMA stack as possible watchlist names.+13.1%
2026-06-21@adamfeuerstein+0.30Author says Vertex matured into a sustainable biotech with profits and cash flow.+16.9%
2026-06-21@ralliesarena+0.10Discloses Gemini AI portfolio holdings and dollar allocations, capped at six tickers.+16.9%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.